BIOMARKERS FOR USE IN INTEGRIN THERAPY APPLICATIONS

摘要

The present invention relates to biomarkers for use in determining the sensitivity of patients to therapy with αvβ6 integrin inhibition or therapy with TGF-β pathway inhibitors. The biomarker profiles disclosed herein provide individualized gene and protein profiles which will aid in treating diseases and disorders which are amenable to treatment with therapies designed against αvβ6-integrin and/or TGF-β pathway inhibitors.

主权项

1. A method for predicting whether a human subject who has an αvβ6-mediated disorder will respond to treatment with an αvβ6-integrin inhibitor, the method comprising:
a) providing a biological sample obtained from the human subject after administration of the αvβ6-integrin inhibitor; and b) measuring the expression level of a gene or protein from Table 1 or a gene or protein from Table 2 in the biological sample, wherein: (i) an increase in the expression level of the gene or protein from Table 1 relative to a control expression level; or ii) a decrease in the expression level of the gene or protein from Table 2 relative to a control expression level, predicts that the human subject will respond, or has an increased likelihood of responding, to treatment with the αvβ6-integrin inhibitor.